Naramig 2.5mg Tablet
PDF Leaflet Revision Date: 25 Aug 2015
Clinical Summary
Quick overview from the medicine insert
Indication
Acute treatment of migraine attacks with or without aura.
Dosage (summary)
1 tablet (2.5 mg) as needed, max 2 tablets in 24 hours.
Onset of Action / Duration
Onset: 2-3 hours, Duration: 6 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy not established; caution in breastfeeding.
Key Drug Interactions
- Ergotamine
- Other triptans
Contraindications
- Hypersensitivity
- Ischaemic heart disease
- CVA or TIA
- Uncontrolled hypertension
- Severe renal or hepatic impairment
Common side effects
- Tingling
- Nausea
- Vomiting
- Heaviness sensation
Counselling Points
- Take at onset of migraine
- Do not exceed recommended dose
- May cause drowsiness
Serious warnings
- Evaluate for cardiovascular disease in at-risk patients
- Not for hemiplegic or basilar migraine
Important Disclaimer
The Naramig 2.5mg Tablet professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
